


## TMC647055 Choline salt

<b>Cat. No.:</b>	HY-15591A
<b>Molecular Formula:</b>	C <sub>37</sub> H <sub>53</sub> N <sub>5</sub> O <sub>8</sub> S
<b>Molecular Weight:</b>	727.91
<b>Target:</b>	HCV
<b>Pathway:</b>	Anti-infection
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 62.5 mg/mL (85.86 mM); ultrasonic and warming and heat to 60°C					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		1.3738 mL	6.8690 mL	13.7380 mL
		<b>5 mM</b>		0.2748 mL	1.3738 mL	2.7476 mL
<b>10 mM</b>		0.1374 mL	0.6869 mL	1.3738 mL		
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (2.86 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	TMC647055 (Choline salt) is a potent nonnucleoside NS5B polymerase inhibitor of HCV replication. TMC647055 Choline salt has potent HCV combine activity with an IC <sub>50</sub> value of 82 nM. TMC647055 Choline salt can be used for the research of Hepatitis C virus (HCV) <sup>[1][2]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	EC90: 0.3 μM (Huh7-Luc cell) <sup>[1]</sup> . EC50: 82 nM (HCV) <sup>[2]</sup>
<b>In Vitro</b>	TMC647055 (Choline salt) has antiviral activity with an EC <sub>90</sub> value of 0.3 μM in Huh7-Luc cells <sup>[1]</sup> . TMC647055 Choline salt has potent combine activity with an EC <sub>50</sub> value of 82 nM in cellular HCV assays <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	TMC647055 Choline salt (compound 18a) (2 mg/kg, iv.; 10mg/kg, po.) shows an acceptable PK profile, characterized by high oral bioavailability and high systemic exposure after single oral dosing of 10 mg/kg, combined with a moderate plasma clearance and low volume of distribution <sup>[2]</sup> .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rats <sup>[2]</sup>
Dosage:	2 mg/kg; 10mg/kg
Administration:	2 mg/kg, iv.; 10mg/kg, po.; singel
Result:	

No.	Cl (L/h/kg)	C <sub>max</sub> (ng/mL)	[Liver] (ng/mL)	L/P	F (%)
TMC647055 (compound 18a)	3.2	440	7800	46	Ø66

## CUSTOMER VALIDATION

- Antiviral Res. 2019 Oct;170:104570.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Sandrine Vendeville, et al. Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055. Bioorg Med Chem Lett. 2012 Jul 1;22(13):4437-43.

[2]. Devogelaere B, et al. TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage. Antimicrob Agents Chemother. 2012 Sep;56(9):4676-4684.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA